How much funding has City Therapeutics raised?

City Therapeutics has raised $234.5M in total funding, most recently a Series B round.

Who are City Therapeutics's investors?

City Therapeutics's investors include Viking Global, ARCH Venture Partners, Sofinnova Investments, Invus, Rock Springs Capital, Slate Path Capital.

When was City Therapeutics founded?

City Therapeutics was founded in 2024.

Where is City Therapeutics headquartered?

City Therapeutics is headquartered in Cambridge, Massachusetts, United States.

What industry is City Therapeutics in?

City Therapeutics operates in Biotech, Healthcare.

City Therapeutics

Engineering the future of RNAi-based medicine

Cambridge, United States · Founded 2024 · $234.5M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Founded: 2024
Business Model: B2B
Website: citytx.com

Total Funding: $234.5M
Last Round: $99.5M Series BJun 2026
Rounds: 2

About

City Therapeutics is a Cambridge, MA-based clinical-stage biopharmaceutical company founded by RNAi pioneers to engineer next-generation small interfering RNA (siRNA) therapeutics. Its platform advances novel trigger molecules and extrahepatic delivery ligands to expand RNAi reach beyond the liver. Lead programs include CITY-FXI for thromboembolic diseases and CITY-RBP4 for Stargardt disease, backed by over $230 million in financing.

Summary

City Therapeutics is a Biotech company based in Cambridge, United States, founded in 2024. It has raised $234.5M in total across 2 rounds, most recently a $99.5M Series B round in Jun 2026. Investors include Viking Global, ARCH Venture Partners and Sofinnova Investments.